Glutamine availability unleashes dendritic cells’ anti-tumor power

Metabolic competition within the tumor microenvironment (TME) shapes the efficacy of anticancer immunity. In the August 3rd issue of Nature, Guo et al. 1 Guo C. You Z. Shi H. Sun Y. Du X. Palacios G. Guy C. Yuan S. Chapman N.M. Lim S.A. et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature. 2023; 620: 200-208https://doi.org/10.1038/s41586-023-06299-8 Crossref PubMed Scopus (8) Google Scholar show that glutamine is an intercellular metabolic checkpoint between cancer and immune cells. Targeting glutamine metabolism in the TME is a promising strategy to improve anti-cancer therapy. Metabolic competition within the tumor microenvironment (TME) shapes the efficacy of anticancer immunity. In the August 3rd issue of Nature, Guo et al. 1 Guo C. You Z. Shi H. Sun Y. Du X. Palacios G. Guy C. Yuan S. Chapman N.M. Lim S.A. et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature. 2023; 620: 200-208https://doi.org/10.1038/s41586-023-06299-8 Crossref PubMed Scopus (8) Google Scholar show that glutamine is an intercellular metabolic checkpoint between cancer and immune cells. Targeting glutamine metabolism in the TME is a promising strategy to improve anti-cancer therapy.